Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av REGN5668 administrert i kombinasjon med Cemiplimab eller REGN4018 hos voksne kvinner med tilbakevendende eggstokkreft

20. september 2026 oppdatert av: Regeneron Pharmaceuticals

Fase 1/2-studie av REGN5668 (MUC16xCD28, en Costimulatory Bispecific) administrert i kombinasjon med Cemiplimab eller REGN4018 (MUC16xCD3)

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

612

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgia, 3000
        • Rekruttering
        • Universitair Ziekenhuis Leuven
      • São Paulo, Brasil, 01509-010
        • Rekruttering
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90619-900
        • Rekruttering
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784-400
        • Rekruttering
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba, São Paulo, Brasil, 18065-100
        • Rekruttering
        • Unimed Sorocaba
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Fullført
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Karmanos Cancer Institute
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Seattle Cancer Care Alliance at South Lake Union - G3630
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite, Auvergne-Rhône, Frankrike, 69310
        • Rekruttering
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon, Bourgogne-Franche-Comté, Frankrike, 21000
        • Rekruttering
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrike, 33076
        • Rekruttering
        • Institut Bergonie
    • Normandy
      • Caen, Normandy, Frankrike, 14076
        • Rekruttering
        • Centre Francois Baclesse (CFB)
      • Girona, Spania, 17007
        • Rekruttering
        • Institut Catala dOncologia Girona
      • Madrid, Spania, 28040
        • Rekruttering
        • Hospital Universitario Fundacion Jimenez
      • Madrid, Spania, 28040
        • Rekruttering
        • Ciudad Universitaria
      • Madrid, Spania, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela, A Coruna, Spania, 15706
        • Rekruttering
        • Hospital Clinico Universitario Santiago de Compostela

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

Andre navn:
  • ubletamig

Administer per the protocol

Andre navn:
  • REGN2810
  • Libtayo®

Administer per the protocol

Eksperimentell: Module 2

REGN5668 and ubamatamab

Administer per the protocol

Andre navn:
  • ubletamig

Administer per the protocol

Andre navn:
  • REGN4018

Administer per the protocol

Andre navn:
  • Kevzara®

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Dose Limiting Toxicities (DLT)
Tidsramme: 42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
Tidsramme: 21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
Tidsramme: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
Tidsramme: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Tidsramme: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Tidsramme: Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tidsramme: Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ORR based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
Tidsramme: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. desember 2020

Primær fullføring (Antatt)

8. november 2028

Studiet fullført (Antatt)

8. november 2028

Datoer for studieregistrering

Først innsendt

9. oktober 2020

Først innsendt som oppfylte QC-kriteriene

9. oktober 2020

Først lagt ut (Faktiske)

19. oktober 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Tilgangskriterier for IPD-deling

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere